Abstract:Background: Deposition of tau aggregates is a pathological hallmark of Alzheimer's disease that is closely linked both spatially and temporally to emergence of neurodegeneration and manifestation of clinical symptoms. There is an urgent need for accurate PET, CSF, and plasma biomarkers of tau pathology to improve the diagnostic process in clinical practice and the selection of participants and monitoring of treatment effects in trials. Recent developments: Innovative second-generation tau-PET tracers with high affinity and selectivity to tau pathology in Alzheimer's disease have enabled detection of tau pathology in medial temporal lobe subregions that are affected in the earliest disease stages. Furthermore, novel but common tau spreading subtypes have been discovered using tau-PET, suggesting much greater interindividual differences in the distribution of tau pathology across the brain than previously assumed. In the CSF biomarker field, novel phosphorylated tau (p-tau) assays have been introduced that better reflect tau tangle load than established CSF biomarkers of tau pathology. The advent of cost-effective and accessible blood-based biomarkers for tau pathophysiology (ie, p-tau181, p-tau217, and p-tau231) might transform the Alzheimer's disease field, as these biomarkers correlate with post-mortem Alzheimer's disease pathology, differentiate Alzheimer's disease from other types of dementia, and predict future progression from normal cognition and mild cognitive impairment to Alzheimer's disease. In controlled investigational settings, improvements in tau-PET and biofluid p-tau markers have led to earlier disease detection, more accurate diagnostic methods, and refinement of prognosis. The anti-tau therapy landscape is rapidly evolving, with multiple ongoing phase 1 and 2 trials of post-translational modification of tau, tau immunotherapy, tau aggregation inhibitors, and targeting production of tau and reduction of intracellular tau levels. Neuroimaging and biofluid tau markers hold potential for optimising such clinical trials by augmenting participant selection, providing evidence of target engagement, and monitoring treatment efficacy. WHERE NEXT?: Major challenges to overcome are the high cost of tau-PET, partial sensitivity to detect early-stage Alzheimer's disease pathology, and off-target tracer binding. Prospective validation studies of biofluid p-tau markers are needed, and assay-related preanalytical and analytical factors need further refinement. Future studies should focus on demonstrating the diagnostic and prognostic accuracy of tau biomarkers-blood-based markers in particular-in non-tertiary settings, such as primary care, which is characterised by a diverse population with medical comorbidities. Large-scale head-to-head studies are needed across different stages of Alzheimer's disease to determine which tau biomarker is optimal in various clinical scenarios, such as early diagnosis, differential diagnosis, and prognosis, and for aspects of clinical trial design, such as proving target engagement, optimising participant selection, and refining monitoring of treatment effects.

Highly sensitive detection of the neurodegenerative biomarker Tau by using the concentration effect of the pyro-electrohydrodynamic jetting

Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders.

Ultrasensitive and point-of-care detection of plasma phosphorylated tau in Alzheimer's disease using colorimetric and surface-enhanced Raman scattering dual-readout lateral flow assay

A Single-Use, In Vitro Biosensor for the Detection of T-Tau Protein, A Biomarker of Neuro-Degenerative Disorders, in PBS and Human Serum Using Differential Pulse Voltammetry (DPV)

Ferritin nanocage-enabled detection of pathological tau in living human retinal cells

Step‐by‐step monitoring of a magnetic and SERS‐active immunosensor assembly for purification and detection of tau protein

Alzheimer's diagnosis beyond cerebrospinal fluid: Probe-Free Detection of Tau Proteins using MXene based redox systems and molecularly imprinted polymers

Ultra‐performance liquid chromatography‐tandem mass spectrometry method for analysis of tau in human cerebrospinal fluid without the need of immunocapture

Sensitive label-free detection of the biomarker phosphorylated tau-217 protein in Alzheimer's disease using a graphene-based solution-gated field effect transistor

An Electrochemical Immunosensor with PEDOT: PSS/MWCNTs-COOH Nanocomposites as a Modified Working Electrode Material for Detecting Tau-441

Progress regarding the context-of-use of tau as biomarker of Alzheimer’s disease and other neurodegenerative diseases

Boosting the sensitivity for tau protein detection with a bifunctional nanoenzyme signal amplifier

Antibody-free quantification of seven tau peptides in human CSF using targeted mass spectrometry

Sensitive colorimetric immunosensor using AuNP-functionalized polymer film for picogram-level detection of Tau protein intermediate aggregates

Focused Ultrasound-mediated Liquid Biopsy in a Tauopathy Mouse Model

Detection and staging of Alzheimer's disease by plasma pTau217 on a high throughput immunoassay platform

Quantitative detection of α-Synuclein and Tau oligomers and other aggregates by digital single particle counting

Improving Sensitivity and Specificity of Amyloid-β Peptides and Tau Protein Detection with Antibiofouling Magnetic Nanoparticles for Liquid Biopsy of Alzheimer's Disease

Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials

Real-time detection of Tau-381 protein using liquid crystal-based sensors for Alzheimer's disease diagnosis

Recent Progress in the Application of Tau Protein Biosensors for Diagnosis of Neurodegenerative Diseases